Migraine pathophysiology;Fisiopatologia de la migrana

Neurologia

Volumn 13, Issue 1, 1998, Pages 29-32

  Pascual, J ^a   Castro, M E ^b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBTYPE; SEROTONIN 1 AGONIST; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; SEROTONIN;

BRAIN BLOOD VESSEL; DRUG BINDING SITE; DRUG MECHANISM; HEADACHE; HUMAN; MIGRAINE; PATHOPHYSIOLOGY; REVIEW; SEROTONINERGIC TRANSMISSION; TRIGEMINAL NERVE; BRAIN; METABOLISM;

BRAIN; HUMANS; MIGRAINE DISORDERS; SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0031911404     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. 2+ channel gene CACNL1A4. Cell 1996; 87: 543-552.
2. Hess EJ. Migraines in mice? Cell 1996; 87: 1.149-1.151.
3. Pardo J, Noya M. La genética de la migraña: se ha escrito el prólogo. Neurología 1997; 12: 275-276.
4. Leira R, Noya M. Fisiopatología de la migraña. Rev Clin Esp 1995; 195: 16-19.
5. Blau JN. Migraine prodromes separated from the aura: complete migraine. Br Med J 1980; 21: 658-660.
6. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996; 119: 355-361.
7. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981; 9: 344-352.
8. Lauritzen MT, Olsen ST, Lassen NA, Paulson OB. Changes in regional cerebral blood flow during the course of classical migraine attacks. Ann Neurol 1983; 13: 633-641.
9. Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990; 28: 791-798.
10. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry 1941; 46: 331-339.
11. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944; 7: 359-390.
12. Milner PM. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leao. Electroencephalogr Clin Neurophysiol 1958; 10: 705-712.
13. Woods RP, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331: 1.689-1.692.
14. Lauritzen M. Pathophysiology of the migraine aura: the spreading depression theory. Brain 1994; 117: 199-210.
15. Weiller C, May A, Limmroth V, Jüptner M, Kaube H, Van Schayck R et al. Brain stem activation in spontaneous human migraine attacks. Nature Med 1995; 1: 658-660.
16. Pascual J. Migraña, serotonina y receptores serotoninérgicos. Neurología 1993; 8: 180-183.
17. Friberg L, Olesen J, Iversen HK, Sperling R. Migraine associated with middle cerebral artery dilation: reversal by sumatriptan. Lancet 1991; 338: 13-17.
18. Goadsby PJ, Edvinson L. The trigeminovascular system and migraine. Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-50.
19. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984; 16: 157-168.
20. Bonvento G, Lacombe P, Mackenzie ET, Fage D, Benavides J, Rouquier L et al. Evidence for different origins of the serotonergic innervation of major cerebral arteries an small pial vessels in the rat. J Neurochem 1991; 56: 681-689.
21. Bonvento G, Mackenzie ET, Edvinsson L. Serotoninergic innervation of the cerebral vasculature: relevance to migraine and ischaemia. Brain Res Rev 1991; 16: 257-263.
22. Moreno MJ, López de Pablo AL, Conde MV, Marco EJ. Cat cerebral arteries are functionally innervated by serotoninergic fibers from central and peripheral origins. Stroke 1995; 26: 271-276.
23. Pascual J. Cefalea en racimos: bases anatómicas y fisiopá tológicas del ataque de dolor. Rev Neurol 1995; 23 (Supl 4): 487-491.
24. Rebeck GW, Maynard KL, Hyman BT, Moskowitz MA. Selective 5-HT1Dα serotonin receptor in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA 1993; 90: 408-412.
25. Hamel E, Fan E, Linville D, Ting V, Villemure JG, Chia LS. Expression of mRNA for the serotonin 5-hydroxytryptamine1Dβ receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 1993; 44: 242-246.
26. Pascual J, Del Arco C, Romón T, Del Olmo, Pazos A. 3H-sumatriptan binding sites in human brain: regonal-dependent labelling to 5-HT1D and 5-HT1F receptors. Eur J Pharmacol 1996; 295: 271-274.
27. Bouchelet I, Cohen Z, Case B, Séguéla P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996; 50: 219-223.
28. Kaune H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109: 788-792.
29. Johnson KW, Audia JE, Cohen ML, Dressman BA, Fritz JE, Kaldor SW et al. The serotonin 1F (5HT1F) receptor subtype: a rational target for migraine drug discovery. Cephalalgia 1997; 17: 245.
30. Pascual J, Del Arco C, Romón T, Del Olmo E, Castro E, Pazos A. Autoradiographic distribution of 3H-sumatriptan-binding sites in postmortem human brain. Cephalalgia 1996; 16: 317-322.
31. Castro ME, Pascual J, Romón T, Del Arco C, Del Olmo E. Differential distribution of 3H-sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 1997; 36: 535-542.
32. Pascual J. Sumatriptán. Neurología 1994; 9: 352-357.